Boston-based biotechnology company targets commercial-scale production beginning with cocoa as it advances a $25 million Series B2 financing round
BOSTON, MA
GALY, a biotechnology company developing plant-based products through biomanufacturing, is advancing its commercial strategy to create a more stable, scalable and resource-efficient supply chain for some of the world’s most widely consumed products, beginning with cocoa.
Founded in 2019 and headquartered in Boston, GALY is developing technology designed to grow plant-based products directly in controlled production environments rather than relying exclusively on traditional agricultural cultivation. The company’s approach combines plant cell biology, fermentation, process optimization and scalable manufacturing.
The broader objective is ambitious: change how essential agricultural ingredients are produced while addressing challenges surrounding supply-chain volatility, land use, water consumption, carbon impact and product consistency.
According to company materials, GALY’s platform is designed to achieve production that is 10 times faster and 500 times more productive, while targeting 100% supply-chain stability and approximately 80% reductions in land, water and carbon requirements compared with conventional approaches.
Cocoa as the Next Commercial Opportunity
GALY is initially focusing its commercial strategy on cocoa, an ingredient facing increasing attention as global prices, climate pressures and supply-chain challenges affect chocolate manufacturers and food companies.
Rather than depending solely on cocoa grown and harvested from farms, GALY aims to produce customizable cocoa through plant-cell cultivation in brewery-style tanks.
The company says its technology allows it to control four important components affecting cocoa flavor — genetics, elicitation, fermentation and roasting — within an integrated system.
GALY has developed a library of more than 200 seed cell lines spanning more than 14 genotypes, according to its investor materials. This approach is intended to provide manufacturers with greater control over flavor profiles while creating a more predictable and traceable ingredient supply.
The company reports that its cocoa can be produced significantly faster than field-grown cocoa while using fewer natural resources and avoiding certain agricultural contaminants, including pesticide residue and mycotoxins.
GALY has completed its self-GRAS process and filed its FDA GRAS dossier. Its current roadmap calls for its first commercial batch to ship in 2026, followed by initial commercial revenue in 2027.
From Biotechnology to Commercial Scale
One of GALY’s differentiators is its focus on moving biotechnology beyond laboratory development and into industrial-scale manufacturing.
The company plans to utilize retrofitted fermentation infrastructure and co-located manufacturing facilities near breweries and sugar mills, an approach intended to reduce capital requirements while allowing production capacity to expand alongside customer demand.
Its proposed scale-up strategy progresses from a proven 2-kiloliter pilot to 6-kiloliter production, followed by multiple 6-kiloliter units and ultimately 50-kiloliter commercial-scale units.
GALY projects revenue of approximately $4 million in 2027, $19 million in 2028, $49 million in 2029, $125 million in 2030, $238 million in 2031 and $422 million in 2032. These figures represent company projections and are forward-looking rather than guaranteed results.
The company currently projects reaching EBITDA break-even in 2028 and becoming cash-flow positive in 2029.
A Platform Extending Beyond Cocoa
While cocoa represents GALY’s immediate commercial focus, the company is building what it describes as a product-agnostic biocrafting platform capable of addressing additional plant-derived materials.
GALY has already demonstrated its technology in cotton. The company reports that its cultivated cotton reached Technology Readiness Level 4 and demonstrated the ability to tune cellulose characteristics through biomanufacturing.
GALY also identifies coffee, vanilla, citrus, saffron and other plant-derived ingredients as potential opportunities within a substantially larger addressable market.
The company’s long-term thesis is that biomanufacturing could complement conventional agriculture by providing manufacturers with a more controlled source of ingredients while reducing exposure to climate events, geographic constraints and unpredictable commodity markets.
Commercial Strategy Targets Food Service First
GALY plans to initially pursue the food-service sector, including chefs, hotels, bakeries, cafés, coffee chains and restaurants, before expanding further into premium chocolate, consumer packaged goods, private-label products and ingredient and flavor companies.
Company materials cite existing commercial activity involving hospitality and food-service organizations as evidence of early market interest.
Rather than attempting to replace the entire cocoa industry, GALY’s strategy centers on capturing a targeted portion of the premium market where quality, consistency, traceability and supply reliability can command significant value.
Financing the Next Stage
GALY is currently pursuing a $25 million Series B2 financing round, according to its materials, with a targeted first close of $15 million.
The company reports having raised approximately $65 million to date and lists a pre-money valuation of approximately $200 million for the current round.
The additional capital is intended to support GALY’s transition from technological validation toward commercial manufacturing and scale.
The company’s leadership team brings experience spanning biotechnology, consulting, venture capital and industrial commercialization, supported by a scientific advisory board with expertise in bioprocess engineering, plant-cell biomanufacturing, biochemistry and systems biology.
GALY has also received industry recognition for its technology, including recognition from the H&M Global Change Award, LVMH Innovation Award, TIME Best Inventions and Edison Awards.
As global food and consumer-product companies confront increasing pressure to secure reliable and sustainable ingredient supplies, GALY is positioning biomanufacturing as another potential path forward.
Its proposition is straightforward but potentially transformative: some of the products traditionally grown across thousands of acres may increasingly be produced through controlled biological manufacturing — delivering the ingredients consumers already know while fundamentally changing how they reach the market.
About GALY
GALY is a Boston-based biotechnology company founded in 2019 that develops plant-based products through cellular agriculture and biomanufacturing. The company is building a scalable platform designed to produce agricultural ingredients and materials in controlled environments, beginning with cocoa and building upon its previous work in cultivated cotton. GALY’s mission centers on developing more predictable and resource-efficient supply chains for globally important products.
Media Contact Details
Liana Zavo
Email: Send Email
